A Phase 2 interventional study of Human serum albumin infusion 20% in Acute Ischemic Stroke From Large Vessel Occlusion, sponsored by Tianjin Huanhu Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by Tianjin Huanhu Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital — 10 open to participants now, 11 under way, 1 of them phase 3. Ischemic Stroke · Tianjin Huanhu Hospital.
Among the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital, this one is the only one that started in 2025, is one of 2 in phase 2, reaches primary completion later than 6 of the 10 other live ones, and was the 11th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →10 of the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital are open now, in 1 country. Recruiting first, the newest first:
Tianjin Huanhu Hospital · Sites in China
Ages 18+
Tianjin Huanhu Hospital · Sites in China
Ages 18+
Tianjin Huanhu Hospital · Sites in China
Ages 18–80
Tianjin Huanhu Hospital · Sites in China
Ages 18+
Tianjin Huanhu Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 60 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 70 across the 6 interventional studies, 3,000 across the 6 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tianjin Huanhu Hospital is the lead sponsor of 26 studies on the registry; 20 are open to participants now.
1 of the studies in Ischemic Stroke by Tianjin Huanhu Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07294391Tianjin Huanhu HospitalThe Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Albumin-assisted therapy has demonstrated good safety and potential neuroprotective effects following mechanical thrombectomy. To further systematically evaluate its efficacy and safety, we are conducting a Phase IIa clinical trial of intra-arterial albumin administration combined with mechanical thrombectomy in patients with acute ischemic stroke. This is a double-center, prospective, open-label, endpoint-blinded, randomized controlled trial designed to preliminarily assess the efficacy and safety of intra-arterial infusion of 20% human albumin after successful recanalization in patients with acute ischemic stroke caused by anterior circulation large-vessel occlusion who undergo mechanical thrombectomy. A total of 60 patients will be enrolled and randomized in a 1:1 ratio by dynamic minimization into two groups: the albumin group (0.6 g/kg of 20% human albumin solution plus mechanical thrombectomy) and the control group (mechanical thrombectomy alone).
The primary objective of this study is to preliminarily evaluate whether intra-arterial infusion of 0.6 g/kg of 20% human albumin via the internal carotid artery immediately after achieving successful recanalization (eTICI ≥ 2b) can reduce infarct volume compared with mechanical thrombectomy alone in patients with anterior circulation large-vessel occlusion who undergo standard mechanical thrombectomy. The secondary objective is to assess the safety and feasibility of intra-arterial infusion of 0.6 g/kg of 20% human albumin immediately after successful recanalization in this patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects assigned to the albumin treatment group after achieving successful recanalization (eTICI ≥ 2b) confirmed by DSA post-thrombectomy will receive a 20% human albumin solution at a dose of 0.60 g/kg. The solution will be administered as a constant-rate infusion into the proximal internal carotid artery over 20 minutes. Vital signs and potential infusion-related reactions must be closely monitored throughout the procedure.
Drug: Human serum albumin infusion 20%
Subjects in the control group who have achieved successful recanalization (eTICI ≥ 2b) as confirmed by DSA following mechanical thrombectomy will not receive the investigational infusion and will undergo standard medical management only.
20% human albumin solution at a dose of 0.60 g/kg will be administered as a constant-rate infusion into the proximal internal carotid artery over 20 minutes.
Growth in infarct volume at 24 (±6) hours after randomization compared to baseline
MRI-DWI
Time frame: at 24 (±6) hours after randomization
Proportion of favorable functional outcome at 90 (±14) days, defined as mRS 0-2
mRS
Time frame: at 90 (±14) day after randomizatio
Infarct volume at 24 (±6) hours
MRI-DWI
Time frame: at 24 (±6) hours after randomization
Proportion of excellent functional at 90 (±14) days, defined as mRS 0-1
mRS
Time frame: at 90 (±14) day after randomization
mRS score at 90 (±14) days
mRS
Time frame: at 90 (±14) days after randomization
Vessel recanalization at 24 (±6) hours
CTA or MRA or DSA
Time frame: at 24 (±6) hours after randomization
NIHSS score at 24 (±6) hours
NIHSS
Time frame: at 24 (±6) hours after randomization
NIHSS score at 7 (±1) days/at discharge
NIHSS
Time frame: at 7 (±1) days/at discharge after randomization
EQ-5D-5L at 90 (±14) days
EQ-5D-5L
Time frame: at 90 (±14) days after randomization
Proportion of Barthel Index ≥95 at 90 (±14) days
Barthel Index
Time frame: at 90 (±14) days after randomization
Incidence of all-cause death within 90 (±14) days
all-cause death
Time frame: at 90 (±14) days after randomization
Incidence of symptomatic intracranial hemorrhage within 24 (±6) hours
according to the modified Heidelberg Bleeding Classification
Time frame: at 24 (±6) hours after randomization
Incidence of intracranial hemorrhage within 24 (±6) hours
all-cause
Time frame: at 24 (±6) hours after randomization
Incidence of serious adverse events within 90 (±14) days
serious adverse events
Time frame: at 90 (±14) days after randomization
Incidence of adverse events within 90 (±14) days
adverse events
Time frame: at 90 (±14) days after randomization
Proportion of early neurological deterioration at 24 hours
defined as ≥ 4-point increase in NIHSS score from baseline
Time frame: at 24 hours after randomization
Proportion of severe disability at 90 (±14) days
defined as mRS 4-6
Time frame: at 90 (±14) days after randomization
Incidence of albumin infusion-associated adverse event within 24 (± 6) hours
albumin infusion-associated adverse event
Time frame: at 24 (± 6) hours after randomization
Blood levels of albumin and BNP at 24 (±6) hours after randomization
albumin and BNP
Time frame: at 24 (±6) hours after randomization
Blood levels of albumin and BNP at 7 (±1) days after randomization or at discharge (whichever occurs first)
albumin and BNP
Time frame: at 7 (±1) days after randomization or at discharge (whichever occurs first)
The along the perivascular space (ALPS) index at 24 (±6) hours after randomization
along the perivascular space index
Time frame: at 24 (±6) hours after randomization
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Dec 2026, 11 months later.
Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 11 months is below that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumins human
Tianjin Huanhu Hospital